Clinical trial
Study of CP-675,206 in Refractory Melanoma
NCT00254579 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00254579 |
|---|---|
| Title | Study of CP-675,206 in Refractory Melanoma |
| Official title | A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Melanoma |
| Intervention type | Drug |
| Interventions | CP-675, 206 |
| Enrollment | 251 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Nov 16, 2005 |
| Last update posted | Jun 7, 2012 |
| Countries | Argentina, Australia, Canada, France, Germany, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: